0000899243-21-007207.txt : 20210218 0000899243-21-007207.hdr.sgml : 20210218 20210218191832 ACCESSION NUMBER: 0000899243-21-007207 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210201 FILED AS OF DATE: 20210218 DATE AS OF CHANGE: 20210218 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BOLNO PAUL CENTRAL INDEX KEY: 0001657710 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37627 FILM NUMBER: 21651388 MAIL ADDRESS: STREET 1: C/O WAVE LIFE SCIENCES LTD. STREET 2: 733 CONCORD AVE. CITY: CAMBRIDGE STATE: MA ZIP: 02138 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Wave Life Sciences Ltd. CENTRAL INDEX KEY: 0001631574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: U0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7 STRAITS VIEW STREET 2: #12-00, MARINA ONE EAST TOWER CITY: SINGAPORE STATE: U0 ZIP: 018936 BUSINESS PHONE: 617-949-2900 MAIL ADDRESS: STREET 1: 733 CONCORD AVENUE CITY: CAMBRIDGE STATE: MA ZIP: 02138 FORMER COMPANY: FORMER CONFORMED NAME: WAVE Life Sciences Ltd. DATE OF NAME CHANGE: 20170516 FORMER COMPANY: FORMER CONFORMED NAME: Wave Life Sciences Ltd. DATE OF NAME CHANGE: 20151106 FORMER COMPANY: FORMER CONFORMED NAME: Wave Life Sciences LTD. DATE OF NAME CHANGE: 20151106 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-01 0 0001631574 Wave Life Sciences Ltd. WVE 0001657710 BOLNO PAUL C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE. CAMBRIDGE MA 02138 1 1 0 0 President and CEO Ordinary Shares 2021-02-01 4 A 0 150000 0.00 A 422181 D Ordinary Shares 2021-02-16 4 S 0 11205 10.57 D 410976 D Share Option (right to buy) 10.48 2021-02-01 4 A 0 200000 0.00 A 2031-02-01 Ordinary Shares 200000 200000 D Consists of restricted share units (RSUs). The RSUs vest in two equal installments on February 15, 2022 and February 15, 2023. On February 16, 2021, the reporting person sold 11,205 ordinary shares solely to cover taxes associated with the vesting of RSUs on February 15, 2021. These sales were made pursuant to a 10b5-1 Trading Plan. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.47 to $10.58 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The option vests as to 50% of the shares on February 15, 2022 and 50% on February 15, 2023. /s/ Paul B. Bolno 2021-02-18